LENZ (lenzilumab) / Humanigen 
Welcome,         Profile    Billing    Logout  
 16 Diseases   3 Trials   3 Trials   683 News 


1234567»
  • ||||||||||  Review, Journal:  A Glimpse for the subsistence from pandemic SARS-CoV-2 infection. (Pubmed Central) -  Jan 14, 2025   
    Although some drug regimens and vaccines have shown safety in trials, none have been entirely successful yet. This review highlights, some of the potential antibodies (tocilizumab, Sarilumab, Avdoralimab, Lenzilumab, Interferon (alfa /beta /gamma)) screened against SARS-CoV-2 and the most promising drugs (Favipiravir, Hydroxychloroquine, Niclosamide, Ribavirin, Baricitinib, Remdesivir, Arbidol Losartan, Ritonavir, Lopinavir, Baloxavir, Nitazoxanide, Camostat) in various stages of development with their synthetic protocol and their clinical projects are discussed to counter COVID -19.
  • ||||||||||  LENZ (lenzilumab) / Humanigen
    Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine (Grand Hall D (Manchester Grand Hyatt San Diego)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2215;    
    P2
    Conclusion : Interim analysis of the PREACH-M trial shows promising results with LENZ/AZA resulting in durable complete responses beyond 12 months with 85% of subjects achieving a complete remission or marrow complete remission without significant LENZ related toxicity. Significantly, 90% of patients with major clone CBL mutations achieved complete remission or marrow complete remission.
  • ||||||||||  LENZ (lenzilumab) / Humanigen, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  C-SMART: COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; (clinicaltrials.gov) -  Aug 24, 2023   
    P3,  N=441, Completed, 
    DOI: 10.1055/s-0042-1744157. Recruiting --> Completed | N=2282 --> 441 | Trial completion date: Dec 2021 --> Apr 2023 | Trial primary completion date: Dec 2021 --> Nov 2022
  • ||||||||||  Management of Complications of BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review () -  Nov 29, 2022 - Abstract #ASH2022ASH_7669;    
    Lenzilumab, is a monoclonal antibody that neutralizes granulocyte-monocyte colony stimulating factor (GM CSF), was also used in preclinical studies and found to be lessening the severity of CRS without dampening CAR-T cell function (Sterner et al., 2019).Infections: The factors which increase the risk of infection in MM patients post-BCMA therapy are >3 prior lines of therapy, B-cell aplasia, infections 30-days before CAR-T, and post CAR-T lymphopenia...In most cases cytopenia would improve over a period of 12-months.Conclusion : Given the recent use of BCMA therapy in RRMM, there is no standard guideline on how to manage the complications associated with it. Larger studies with longer follow up needs to be conducted, to address the safety of the therapy for better patient outcome
  • ||||||||||  bococizumab (RN316) / Pfizer, lenzilumab (KB003) / Humanigen
    Journal:  Reduction of therapeutic antibody self-association using yeast-display selections and machine learning. (Pubmed Central) -  Nov 27, 2022   
    Moreover, negatively charged mutations in the heavy chain CDR2 of bococizumab, adjacent to its paratope, were effective at reducing self-association without reducing affinity. Interestingly, most of the bococizumab variants with reduced self-association also displayed improved folding stability and reduced nonspecific binding, revealing that this approach may be particularly useful for identifying antibody candidates with attractive combinations of drug-like properties.Abbreviations: AC-SINS: affinity-capture self-interaction nanoparticle spectroscopy; CDR: complementarity-determining region; CS-SINS: charge-stabilized self-interaction nanoparticle spectroscopy; FACS: fluorescence-activated cell sorting; Fab: fragment antigen binding; Fv: fragment variable; IgG: immunoglobulin; QD: quantum dot; PBS: phosphate-buffered saline; V: variable heavy; V: variable light.
  • ||||||||||  Iomab-B (I-131-apamistamab) / Actinium, Immedica
    An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (Hall D (Ernest N. Morial Convention Center)) -  Nov 4, 2022 - Abstract #ASH2022ASH_6475;    
    P1
    Within the last year alone, the FDA approved brexu-cel for adults w/ R/R B-ALL and expanded indications for liso-cel and axi-cel to include DLBCL w/ primary refractory disease or early first relapse...Anti-cytokine therapies beyond tocilizumab (anti-IL-6R mAb) are being investigated for prevention of CRS/ICANS, including lenzilumab (anti-GM-CSF mAb) and anakinra (IL-1R antagonist)...Accordingly, we designed and initiated a pilot study of Iomab-B w/ adoptive cellular therapy (Iomab-ACT; Fig 1A).Study design and Iomab-ACT is a single-institution pilot study of Iomab-B (w/o chemotherapy) as conditioning prior to 19-28z CAR-T in adults w/ R/R B-ALL or DLBCL (NCT04512716)...Unexpected toxicity (given low dose of ARC) observed in 1 pt included severe trilineage cytopenias lasting >8 wks (requiring RBC/PLT transfusion support, G-CSF, romiplostim) w/o marrow hypoplasia and w/o other apparent neoplastic or drug-induced etiology; this met criteria for dose-limiting toxicity and we will monitor in the next 3 pts...Key exploratory objectives include describing changes in circulating immune cells following ARC and 19-28z CAR T-cells w/spectral cytometry using a custom antibody panel (Fig 1B) and cytokine levels in cerebrospinal fluid. We hope to generate preliminary data to guide further study of CD45-targeted ARCs prior to CAR-T and other forms of adoptive cellular therapy.
  • ||||||||||  Journal:  Current and future therapeutic options for COVID-19 (Pubmed Central) -  Sep 6, 2022   
    Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.
  • ||||||||||  LENZ (lenzilumab) / Humanigen
    Trial completion, Trial completion date:  ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 (clinicaltrials.gov) -  Jun 7, 2022   
    P2,  N=473, Completed, 
    Hospitalised hypoxemic patients with COVID-19 with baseline CRP <150 mg/L derived the greatest clinical benefit from treatment with lenzilumab. Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Apr 2022
  • ||||||||||  lenzilumab (KB003) / Humanigen
    Lenzilumab (Twitter) -  May 7, 2022   
  • ||||||||||  lenzilumab (KB003) / Humanigen
    Lenzilumab (Twitter) -  Apr 8, 2022